Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02019667 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 24, 2013
Last Update Posted : October 26, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Objective:
To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.
Study Population:
Twenty-two children and adults with SSADH deficiency.
Design:
Double-blind, cross-over, phase II clinical trial. SGS-742 is a GABA (B) receptor antagonist that has shown to be safe and well-tolerated in clinical trials in adults with cognitive impairment. In addition, preliminary data in the SSADH knockout mouse model suggest efficacy in this specific syndrome. The primary outcome measure will be a change in the Auditory Comprehension subtest of the Neuropsychological Assessment Battery Language Module score; the secondary outcome measure will be a change in cortical excitation and inhibition measured by transcranial magnetic stimulation (TMS). Additional evaluations will include neurological and neuropsychological examinations, magnetic resonance spectroscopy and CSF collection to measure GABA levels. The trial will have a baseline phase in which each patient will undergo a neurological examination and a neuropsychological evaluation. During the subsequent treatment phase, patients will be randomized to SGS-742, supplied by IRIX Pharmaceuticals, and based on weight given a maximum tolerated dose not to exceed 600 mg t.i.d. orally, or placebo, each for 6 months. Patients will then have repeat TMS, neurological and neuropsychological evaluations, followed by cross-over to the alternate treatment arm, and re-evaluation after 6 months.
Outcome Measures:
The primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metabolic Disease Seizures | Drug: SGS-742 Drug: Placebo | Phase 2 |
Objective:
To perform a clinical trial assessing the safety, tolerability and efficacy of the GABA(B) receptor antagonist SGS-742 in patients with SSADH deficiency.
Study Population:
Twenty-two children and adults with SSADH deficiency.
Design:
Double-blind, cross-over, phase II clinical trial. SGS-742 is a GABA (B) receptor antagonist that has shown to be safe and well-tolerated in clinical trials in adults with cognitive impairment. In addition, preliminary data in the SSADH knockout mouse model suggest efficacy in this specific syndrome. The primary outcome measure will be a change in the Auditory Comprehension subtest of the Neuropsychological Assessment Battery Language Module score; the secondary outcome measure will be a change in cortical excitation and inhibition measured by transcranial magnetic stimulation (TMS). Additional evaluations will include neurological and neuropsychological examinations, magnetic resonance spectroscopy and CSF collection to measure GABA levels. The trial will have a baseline phase in which each patient will undergo a neurological examination and a neuropsychological evaluation. During the subsequent treatment phase, patients will be randomized to SGS-742, supplied by IRIX Pharmaceuticals, and based on weight given a maximum tolerated dose not to exceed 600 mg t.i.d. orally, or placebo, each for 6 months. Patients will then have repeat TMS, neurological and neuropsychological evaluations, followed by cross-over to the alternate treatment arm, and re-evaluation after 6 months.
Outcome Measures:
The primary outcome measures for drug efficacy will be performance on neuropsychological testing and responses to parent questionnaire. The secondary outcome measure will be TMS parameters of cortical excitation and inhibition. The outcome measures for safety will include clinical examination and neuropsychological tests.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 19 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency |
| Study Start Date : | December 20, 2013 |
| Estimated Primary Completion Date : | January 31, 2019 |
| Estimated Study Completion Date : | January 31, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: phase II
study drug or placebo (blinded)
|
Drug: SGS-742 Drug: Placebo |
|
Experimental: phase I for 6 months
Study drug or placebo (blinded) for 6 months
|
Drug: SGS-742 Drug: Placebo |
|
Experimental: phase I
study drug or placebo (blinded)
|
Drug: SGS-742 Drug: Placebo |
|
Experimental: phase II crossover
crossover study drug or placebo blinded
|
Drug: SGS-742 Drug: Placebo |
- Performance on neurological testing and responses to parent questionnaire [ Time Frame: on-going ]
- TMS parameters of cortical excitation and inhibition [ Time Frame: on-going ]
- Clinical examination and neuropsychological tests [ Time Frame: on-going ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA
- Aged 4 years or older
- 4-hydroxybutyric aciduria (gamma-hydroxybutyric aciduria) on two separate tests
- Documented succinic semialdehyde dehydrogenase enzyme deficiency
- Patients must have clinical features consistent with SSADH deficiency including developmental delay especially deficit in expressive language, hypotonia, ataxia, seizures, and other neuropsychiatric symptoms including sleep disturbances , attention deficit, anxiety, obsessivecompulsive disorder, and autistic traits
- During the study, women of child-bearing potential must use a reliable method of birth control until one month after the final drug taper is complete.
EXCLUSION CRITERIA
- Current alcohol use (>14 drinks/wk in men and >7 drinks/wk in women or or recreational drug use
- Contraindications to MRI: metal in the body including pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have
- Claustrophobia
- Cannot lie comfortably flat on the back for up to 2h in the MRI scanner
- Patients with a history of other major medical disorders with clinical fluctuations, or requiring therapy that might affect study participation or drug response such as severe depression or psychoses, renal or hepatic disease.
- Patients requiring treatment with drugs known to affect the GABAergic system, including vigabatrin and benzodiazepines.
- Pregnant and lactating women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02019667
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | |
| Bethesda, Maryland, United States, 20892 | |
| United States, Washington | |
| Washington State University | |
| Pullman, Washington, United States | |
| Principal Investigator: | Sara K Inati, M.D. | National Institute of Neurological Disorders and Stroke (NINDS) |
Additional Information:
Publications:
| Responsible Party: | National Institute of Neurological Disorders and Stroke (NINDS) |
| ClinicalTrials.gov Identifier: | NCT02019667 History of Changes |
| Other Study ID Numbers: |
140033 14-N-0033 |
| First Posted: | December 24, 2013 Key Record Dates |
| Last Update Posted: | October 26, 2018 |
| Last Verified: | October 22, 2018 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ):
|
GABA Seizures Neurotransmitters |
Additional relevant MeSH terms:
|
Seizures Metabolic Diseases Amino Acid Metabolism, Inborn Errors Developmental Disabilities Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Metabolism, Inborn Errors |
Genetic Diseases, Inborn Neurodevelopmental Disorders Mental Disorders (3-aminopropyl)(n-butyl)phosphinic acid Neuroprotective Agents Protective Agents Physiological Effects of Drugs GABA Antagonists GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |